|
Preventive
effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea
in advanced non-small-cell lung cancer
Mori
K, Kondo T, Kamiyama Y, Kano Y, Tominaga K
Department
of Thoracic Diseases, Tochigi Cancer Center, 4-9-13 Yonan, Utsunomiya, 320,
Tochigi, Japan
Purpose.
Kampo medicine Hangeshashin-to (TJ-14) which contains baicalin, a beta-glucuronidase
inhibitor, alleviates diarrhea induced by irinotecan (CPT-11). We conducted a
randomized comparative trial to investigate whether support with TJ-14 would
prevent and control CPT-11-induced diarrhea.
Methods.
Of 44 previously untreated patients with advanced non-small-cell lung cancer
randomized, 41 (18 TJ-14 group, 23 control group) were available for evaluation.
The chemotherapy regimen consisted of a combination of cisplatin and CPT-11.
TJ-14 (7.5 g/day) was administered orally.
Results.
Of the 41 patients, 39 experienced diarrhea.
Compared with the control group, the TJ-14 group showed a significant
improvement in diarrhea grades ( P=0.044) as well as a reduced frequency of
diarrhea grades 3 and 4 (one patient versus ten patients; P=0.018).
However, the two groups showed no differences in the frequency of diarrhea or
the number of days the symptoms continued.
This study was stopped at an interim evaluation.
Conclusion.
TJ-14 was effective in preventing and controlling CPT-11-induced diarrhea.
PMID:
12687289 [PubMed - as supplied by publisher]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12687289&dopt=Abstract
|
